Search Results - "Liang, Jane"

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial by Wu, Yi-Long, Cheng, Ying, Zhou, Xiangdong, Lee, Ki Hyeong, Nakagawa, Kazuhiko, Niho, Seiji, Tsuji, Fumito, Linke, Rolf, Rosell, Rafael, Corral, Jesus, Migliorino, Maria Rita, Pluzanski, Adam, Sbar, Eric I, Wang, Tao, White, Jane Liang, Nadanaciva, Sashi, Sandin, Rickard, Mok, Tony S

“…Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine…”
Get full text

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study by Kantarjian, Hagop M., DeAngelo, Daniel J., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan M., Jabbour, Elias, Wang, Tao, Liang White, Jane, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S.

“…Background Inotuzumab ozogamicin (InO) is an antibody‐drug conjugate used for adults with relapsed/refractory B‐cell precursor (BCP) acute lymphoblastic…”
Get full text

Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD by Charu, Vivek, Liang, Jane W., Mannalithara, Ajitha, Kwong, Allison, Tian, Lu, Kim, W. Ray

“…Ensemble machine-learning methods, like the superlearner, combine multiple models into a single one to enhance predictive accuracy. Here we explore the…”
Get full text

Profiling DNA methylation differences between inbred mouse strains on the Illumina Human Infinium MethylationEPIC microarray by Gujar, Hemant, Liang, Jane W, Wong, Nicholas C, Mozhui, Khyobeni

“…The Illumina Infinium MethylationEPIC provides an efficient platform for profiling DNA methylation in humans at over 850,000 CpGs. Model organisms such as mice…”
Get full text

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer by RAMALINGAM, Suresh S, BLACKHALL, Fiona, LETRENT, Stephen P, RUIZ-GARCIA, Ana, TAYLOR, Ian, LIANG, Jane Q, CAMPBELL, Alicyn K, O'CONNELL, Joseph, BOYER, Michael, KRZAKOWSKI, Maciej, BARRIOS, Carlos H, PARK, Keunchil, BOVER, Isabel, DAE SEOG HEO, ROSELL, Rafael, TALBOT, Denis C, FRANK, Richard

“…This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2,…”
Get full text

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial by Ramalingam, Suresh S, Prof, Jänne, Pasi A, Prof, Mok, Tony, Prof, O'Byrne, Kenneth, Prof, Boyer, Michael J, Prof, Von Pawel, Joachim, Prof, Pluzanski, Adam, MD, Shtivelband, Mikhail, MD, Docampo, Lara Iglesias, MD, Bennouna, Jaafar, MD, Zhang, Hui, PhD, Liang, Jane Q, PhD, Doherty, Jim P, PhD, Taylor, Ian, PhD, Mather, Cecile B, MS, Goldberg, Zelanna, MD, O'Connell, Joseph, MD, Paz-Ares, Luis, Prof

“…Summary Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor. Findings from a phase 2 study in non-small cell lung cancer showed…”
Get full text

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma by KIRKWOOD, John M, LORIGAN, Paul, HERSEY, Peter, HAUSCHILD, Axel, ROBERT, Caroline, MCDERMOTT, David, MARSHALL, Margaret A, GOMEZ-NAVARRO, Jesus, LIANG, Jane Q, BULANHAGUI, Cecile A

“…Purpose: This phase II study assessed the antitumor activity of tremelimumab, a fully human, anti–CTL-associated antigen 4 monoclonal antibody, in patients…”
Get full text

Matrix Linear Models for High-Throughput Chemical Genetic Screens by Liang, Jane W, Nichols, Robert J, Sen, Śaunak

“…We develop a flexible and computationally efficient approach for analyzing high-throughput chemical genetic screens. In such screens, a library of genetic…”
Get full text

A likelihood‐based approach to assessing frequency of pathogenicity among variants of unknown significance in susceptibility genes by Yang, Yunqi, Hong, Christine, Liang, Jane W., Gruber, Stephen, Parmigiani, Giovanni, Idos, Gregory, Braun, Danielle

“…Commercialized multigene panel testing brings unprecedented opportunities to understand germline genetic contributions to hereditary cancers. Most genetic…”
Get full text

Multi-syndrome, multi-gene risk modeling for individuals with a family history of cancer with the novel R package PanelPRO by Lee, Gavin, Liang, Jane W, Zhang, Qing, Huang, Theodore, Choirat, Christine, Parmigiani, Giovanni, Braun, Danielle

“…Identifying individuals who are at high risk of cancer due to inherited germline mutations is critical for effective implementation of personalized prevention…”
Get full text

Statistical methods for Mendelian models with multiple genes and cancers by Liang, Jane W., Idos, Gregory E., Hong, Christine, Gruber, Stephen B., Parmigiani, Giovanni, Braun, Danielle

“…Risk evaluation to identify individuals who are at greater risk of cancer as a result of heritable pathogenic variants is a valuable component of…”
Get full text

Low infectivity among asymptomatic patients with a positive severe acute respiratory coronavirus virus 2 (SARS-CoV-2) admission test at a tertiary care center, 2020–2022 by Tayyar, Ralph, Kiener, Melanie A., Liang, Jane W., Contreras, Gustavo, Rodriguez-Nava, Guillermo, Zimmet, Alex N., Contag, Caitlin A., Srinivasan, Krithika, McIntyre, Karen, Subramanian, Aruna, Shepard, John, Tompkins, Lucy S., Pinsky, Benjamin A., Salinas, Jorge L.

“…We used a strand-specific RT-qPCR to evaluate viral replication as a surrogate for infectiousness among 242 asymptomatic inpatients with a positive severe…”
Get full text

Long-term Low-Molecular-Weight Heparin and the Post-Thrombotic Syndrome: A Systematic Review by Hull, Russell D., MBBS, MSc, Liang, Jane, MSc, Townshend, Grace, MSc

“…Abstract Objective Post-thrombotic syndrome causes considerable morbidity. The Home-LITE study showed a lower incidence of post-thrombotic syndrome and venous…”
Get full text

The effect of socioeconomic status on pediatric heart transplant outcomes at a single institution between 2013 and 2022 by Armstrong, Allison, Liang, Jane W., Char, Danton, Hollander, Seth A., Pyke‐Grimm, Kimberly A.

“…Background Disparities in pediatric heart transplant outcomes based on socioeconomic status (SES) have been previously observed. However, there is a need to…”
Get full text

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors by JÄNNE, Pasi A, BOSS, David S, MILLHAM, Robert, TAYLOR, Ian, GAIL ECKHARDT, S, SCHELLENS, Jan H. M, ROSS CAMIDGE, D, BRITTEN, Carolyn D, ENGELMAN, Jeffrey A, GARON, Edward B, FENG GUO, WONG, Steven, JANE LIANG, LETRENT, Stephen

“…PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. This…”
Get full text

Evaluating the utility of multi-gene, multi-disease population-based panel testing accounting for uncertainty in penetrance estimates by Liang, Jane W., Christensen, Kurt D., Green, Robert C., Kraft, Peter

“…Panel germline testing allows for the efficient detection of deleterious variants for multiple conditions, but the benefits and harms of identifying these…”
Get full text

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin by Jabbour, Elias, Advani, Anjali S., Stelljes, Matthias, Stock, Wendy, Liedtke, Michaela, Gökbuget, Nicola, Martinelli, Giovanni, O'Brien, Susan, White, Jane Liang, Wang, Tao, Luisa Paccagnella, M., Sleight, Barbara, Vandendries, Erik, DeAngelo, Daniel J., Kantarjian, Hagop M.

“…Karyotype is frequently used to predict response and outcome in leukemia. This post hoc exploratory analysis evaluated the relationship between baseline…”
Get full text

Low infectivity among asymptomatic patients with a positive SARS-CoV-2 admission test at a tertiary-care center, 2020–2022 by Tayyar, Ralph, Kiener, Melanie, Liang, Jane W., Anez, Gustavo Contreras, Nava, Guillermo Rodriguez, Zimmet, Alex, Contag, Caitlin A., Srinivasan, Krithika, Tompkins, Lucy, Subramanian, Aruna, Shepard, John, Pinsky, Benjamin A., Salinas, Jorge

“…Background: Many hospitals have implemented admission SARS-CoV-2 testing to evaluate for the need for transmission-based precautions. However, a positive test…”
Get full text

Trajectories of SARS-CoV-2 viral shedding among admitted patients at a tertiary-care center in California, 2020–2022 by Tayyar, Ralph, Kiener, Melanie, Ferguson, Jessica, Liang, Jane W., Anez, Gustavo Contreras, Nava, Guillermo Rodriguez, Contag, Caitlin A., Zimmet, Alex, Srinivasan, Krithika, Shepard, John, Pinsky, Benjamin A., Tompkins, Lucy, Subramanian, Aruna, Salinas, Jorge

“…Background: SARS-CoV-2 viral load decreases over time after illness onset. However, immunocompromised patients may take longer for viral load decrease or have…”
Get full text

Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review by Hull, Russell D, Liang, Jane, Bergqvist, David, Yusen, Roger D

“…Surgeons consider the benefit-to-harm ratio when making decisions regarding the use of anticoagulant venous thromboembolism (VTE) prophylaxis. We evaluated the…”
Get more information